ANTX — AN2 Therapeutics Share News
0.000.00%
Last trade - 00:00AN2 Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: An2 Therapeutics And Dndi Collaborate On Clinical Development Of Promising New Oral Compound To Treat Chronic Chagas Disease
Brief: An2 Therapeutics To Initiate Phase 2 Trial Later This Year
Brief: AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million
Brief: AN2 Provides Strategic Update For Phase 3 Ebo-301 Trial In Treatment Refractory Mac Lung Disease
Brief: AN2 Therapeutics Receives Continuation Grant To Discover Novel Boron Based Therapies For Tuberculosis And Malaria
Brief: AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
Brief: BML Investment Partners Reports 14.2% Passive Stake In AN2 Therapeutics
U.S. STOCKS ON THE MOVE-Revance Therapeutics, Insulet, StepStone
U.S. STOCKS ON THE MOVE-Synchrony, Grindr, Blend Labs
AN2 Therapeutics plunges on termination of lung disease trial
Brief: AN2 Therapeutics Inc - Approved A Reduction In Force That Is Intended To Result In Termination Of Approximately 50% Of Company's Employee Workforce
Brief: AN2 Therapeutics Provides Update On Ebo-301 Phase 2/3 Study Evaluating Epetraborole For Treatment-Refractory Mycobacterium Avium Complex (Mac) Lung Disease
Brief: Octagon Capital Advisors Reports 10.1% Passive Stake In AN2 Therapeutics As Of June 13
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap
AN2 Therapeutics to pause enrollment in lung disease study, shares plummet